Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1964)	1/15/2008 10:25:18 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

POZN opened with a small UG & has traded above its Sep7 H of 13.20 in spite of the poor cooperation from the general market.<g> The stock is up 13.15% bigcharts.marketwatch.com It announced today that it has submitted the findings from the short-term human volunteer study of the genotoxic potential of Treximet (formerly known as Trexima) to the FDA. No chromosomal aberrations were induced in peripheral blood lymphocytes when Treximet was administered to volunteers for seven days. If POZN can close above its SepH, will see if it can deal with the resistance at the $15 level.<g> bigcharts.marketwatch.com Bernard